Angiotensin-receptor blockers and cancer: Urgent regulatory review needed

The Lancet Oncology

Volumn 11, Issue 7, 2010, Pages 605-606

  Nissen, S E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TELMISARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST;

CANCER RESEARCH; CANCER RISK; CLINICAL RESEARCH; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; PUBLICATION; REVIEW; CHEMICALLY INDUCED DISORDER; DRUG CONTROL; NEOPLASM; NOTE; PATIENT SELECTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; DRUG AND NARCOTIC CONTROL; HUMANS; NEOPLASMS; PATIENT SELECTION;

EID: 77954888779     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70142-X     Document Type: Note

References (6)

1. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010, published online June 14. 10.1016/S1470-2045(10)70106-6.
2. Nissen SE, Wolski K Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
3. Colhoun HM Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009, 52:1755-1765. SDRN Epidemiology Group.
4. Mukherjee D, Nissen SE, Topol EJ Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001, 286:954-959.
5. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008, 358:252-260.
6. Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance. Arch Intern Med 2009, 169:1976-1985.